American Society of Hirudotherapy

Anticoagulation in the management of neonatal cerebral sinovenous thrombosis: a systematic review and meta-analysis

Review published in Developmental medicine and child neurology (2018)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Meta-analysisClinical LiteratureDrug DevelopmentRossor et al. · Developmental medicine and child neurology, 2018

Abstract

AIM: To determine whether anticoagulation therapy (ACT) in the treatment of neonatal cerebral sinovenous thrombosis (CSVT) improves outcomes, in the presence or absence of pre-existing intracerebral haemorrhage (ICH). METHOD: We searched CENTRAL, MEDLINE, Embase, CINAHL, the Web of Science, and clinical trial databases. We considered data from retrospective and prospective cohort studies, case series, and randomized controlled studies evaluating outcomes of CSVT treated with anticoagulation or no anticoagulation. Studies were included if they involved infants either younger than 28 days of age or younger than 44 weeks postmenstrual age at the time of diagnosis of CSVT in which ACT was considered. RESULTS: Seven non-randomized studies were included in meta-analysis. ACT had no significant effect on mortality before discharge either in the presence or absence of pre-existing ICH, nor on the incidence of extension of pre-existing ICH. ACT was associated with a reduced risk of propagation of thrombus (risk ratio 0.14, 95% confidence interval 0.03-0.72). INTERPRETATION: There are no randomized trials assessing the safety and efficacy of ACT in the treatment of neonatal CSVT. The results of this meta-analysis would justify a position of equipoise and support the need for well-designed randomized controlled trials of ACT in this population. WHAT THIS PAPER ADDS: No randomized studies have evaluated anticoagulation therapy (ACT) in neonatal cerebral sinovenous thrombosis. ACT may reduce thrombus propagation. No evidence of increased morbidity or mortality with ACT was demonstrated. A position of equipoise is justified, supporting the need for placebo-controlled randomized trials.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleMeta-AnalysisSystematic Review
Indexed MeSH termsAnticoagulantsCerebral HemorrhageHumansInfant, NewbornSinus Thrombosis, Intracranial

Summary

This meta-analysis of seven non-randomized studies of neonatal cerebral sinovenous thrombosis found anticoagulation reduced thrombus propagation (risk ratio 0.14) with no significant effect on mortality or extension of pre-existing haemorrhage; no randomized trials exist.

Context

This systematic review and meta-analysis evaluated whether anticoagulation therapy improves outcomes in neonatal cerebral sinovenous thrombosis, analyzing seven non-randomized studies. It found that anticoagulation may reduce thrombus propagation without increasing mortality or worsening pre-existing intracranial hemorrhage, though no randomized trials exist. The authors call for well-designed placebo-controlled randomized trials in this population. The abstract does not mention leeches, hirudotherapy, hirudin, or any leech-derived compounds.

Citation

Reference (Vancouver style)

Rossor T, Arichi T, Bhate S, Hart AR, Raman Singh R. Anticoagulation in the management of neonatal cerebral sinovenous thrombosis: a systematic review and meta-analysis. Dev Med Child Neurol. 2018;60(9):884-891. doi:10.1111/dmcn.13760. PMID: 29675941

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.